Novo Nordisk Oral Semaglutide Shows Pediatric Breakthrough
Bagsværd, Denmark – April 23, 2026 In a major advancement for pediatric diabetes care, Novo Nordisk announced positive Phase...
GLP-1 Therapy
Advertisement
Novo Nordisk Secures EMA Approval for Wegovy Delivery Flexibility
Bagsværd, Denmark | April 9, 2026 Novo Nordisk has announced that the European Medicines Agency (EMA) has approved an...
Novo Nordisk Wegovy HD Approved with 20% Weight Loss
BAGSVÆRD, Denmark, March 19, 2026 Novo Nordisk A/S announced that the U.S. Food and Drug Administration (FDA) has approved...
Cipla Launches Generic Liraglutide in US
MUMBAI, India & WARREN, N.J., USA – February 27, 2026 Cipla Limited announced the U.S. launch of Liraglutide Injection...
Hanmi Expands GLP-1 Obesity Drug Reach Through Mexico Deal
SEOUL, SOUTH KOREA | January 27, 2026 — Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced a...
Advertisements
TempraMed Expands Digital Health With VIVI Cap Smart
VANCOUVER, BC, Dec. 26, 2025 — TempraMed Technologies Ltd., a medical technology innovator focused on temperature-sensitive medication protection, has...
China Supreme Court Upholds Novo Nordisk Semaglutide Patent
BAGSVAERD, DENMARK | December 31, 2025 — Novo Nordisk announced that China’s Supreme People’s Court has upheld the validity...
Health Canada Grants Conditional Approval for Wegovy® in MASH
MISSISSAUGA, Ontario — December 15, 2025 — Novo Nordisk Canada Inc. announced that Health Canada has granted conditional marketing...
Mazdutide 9mg Enters NMPA Review, Advancing Obesity Treatment
BEIJING, China, Nov. 25, 2025 — Innovent Biologics and Eli Lilly announced that the supplementary application for Mazdutide 9mg...
Emcure Partners with Novo Nordisk to Bring Semaglutide to India
Bengaluru, November 10, 2025 — Global diabetes-care leader Novo Nordisk India has entered into a strategic partnership with Emcure...
Advertisement
